Antibody immunoprophylaxis and immunotherapy for influenza virus infection: Utilization of monoclonal or polyclonal antibodies?

References

• Oritz JR, Neuzil KM, Shay DK, Rue TC, Neradilek MB, Zhou H, Seymour CW, Hooper LG, Cheng PY, Goss CH, et al. The burden of influenza-associated critical illness hospitalisations. Crit. Care Med. 2014;42:2325–32. doi:10.1097/CCM.0000000000000545. PMID:25148596
   PubMed Web of Science ®Google Scholar
• Berry CM. Towards a universal influenza virus vaccine eliciting broadly neutralizing haemagglutinin antibodies. J Vaccines Vaccination. 2015;6:303. doi:10.4172/2157-7560.1000303
   Google Scholar
• Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 2012;337:183–186. doi:10.1126/science.1225416. PMID:22798606
   PubMed Web of Science ®Google Scholar
• Clementi N, Criscuolo E, Castelli M, Clementi M. Broad-range neutralizing anti-influenza A human monoclonal antibodies: New perspectives in therapy and prophylaxis. The New Microbiol. 2012;35:399–406. PMID:23109007
   PubMed Web of Science ®Google Scholar
• Lauresen NS, Wilson IA. Broadly neutralizing antibodies against influenza viruses. Antiviral. Res. 2013;98:476–483. doi:10.1016/j.antiviral.2013.03.021. PMID:23583287
   PubMed Web of Science ®Google Scholar
• Choi WS, Baek JH, Seo YB, Kee SY, Jeong HW, Lee HY, Eun BW, Choo EJ, Lee J, Kim YK, et al. Transgovernmental enterprise for pandemic influenza in Korea. Severe influenza treatment guideline. Korean J. Intern. Med. 2014;29:132–147. doi:10.3904/kjim.2014.29.1.132. PMID:24574848
   PubMed Web of Science ®Google Scholar
• Zambon M. Developments in the treatment of severe influenza: Lessons from the pandemic of 2009 and new prospects for therapy. Curr. Opin. Infect. Dis. 2014;27:560–565. doi:10.1097/QCO.0000000000000113. PMID:25333476
   PubMed Web of Science ®Google Scholar
• Jiang W, Chen H, Ren H, Huang X, Wang G, Chen Z, Chen L, Chen Z, Zhou P. Heterologous DNA virus-like –particle prime-boost vaccine elicits broad protection against both Group 1 ad 2 influenza A viruses. J. Virol. 2017;91:e02052–16. doi:10.1128/JVI.02052-16. PMID:28179535
   PubMed Web of Science ®Google Scholar
• Stevens NE, Hatjopolous A, Fraser CK, Alsharifi M, Diener KR, Hayball JD. Preserved antiviral adaptive immunity following polyclonal antibody immunotherapy for severe murine influenza infection. Sci. Rep. 2016;6:29154. doi:10.1038/srep29154. PMID:27380890
   PubMed Web of Science ®Google Scholar
• Gust I. Role of passive immunotherapies in managing infectious outbreaks. Biologicals. 2012;40:196–199. doi:10.1016/j.biologicals.2012.01.001. PMID:22361391
   PubMed Web of Science ®Google Scholar
• Angeletti D, Gibbs JS, Angel M, Kosik I, Hickman HD, Frank GM, Das SR, Wheatley AK, Prabhakaran M, Leggat DJ, et al. Defining B cell immunodominance to viruses. Nature Immunol. 2017;18:456–463. doi:10.1038/ni.3680
   PubMed Web of Science ®Google Scholar
• Berry CM. Understanding interferon subtype therapy for viral infections: Harnessing the power of the innate immune system. Cytokine and Growth Factor Reviews. 2016;31:83–90. doi:10.1016/j.cytogfr.2016.08.001. PMID:27544015
   PubMed Web of Science ®Google Scholar
• Thomson CA, Wang Y, Jackson LM, Olson M, Wang W, Liavonchanka A, Keleta L, Silva V, Diederich S, Jones RB, et al. Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the haemagglutinin stem. Front. Immunol. 2012;3:87. doi:10.3389/fimmu.2012.00087. PMID:22586427
   PubMed Web of Science ®Google Scholar
• Murphy BR, Kaseld JA, Chanock RM. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N. Engl. J. Med. 1972;286:1329–32. doi:10.1056/NEJM197206222862502. PMID:5027388
   PubMed Web of Science ®Google Scholar
• Jiang L, Fantoni G, Couzens L, Gao J, Plant W, Ye Z, Eichelberger MC, Wan H. Comparative efficacy of monoclonal antibodies that bind to different epitopes of the 2009 pandemic H1N1 influenza virus neuraminidase. J. Virol. 2015;90:117–128. doi:10.1128/JVI.01756-15. PMID:26468531
   PubMed Web of Science ®Google Scholar
• Van den Hoecke S, Ehrhardt K, Kolpe A, El Bakkouri K, Deng L, Grootaert H, Schoonooghe S, Smet A, Bentahir M, Roose K, et al. Hierarchical and redundant roles of activating FcγRs in protection against influenza disease by M2e-specific IgG1 and IgG2a antibodies. J. Virol. 2017;91:e02500–16. doi:10.1128/JVI.02500-16. PMID:28077656
   PubMed Web of Science ®Google Scholar
• Kalenik B, Sawicka R, Gora-Sochacka A, Sirko A. Influenza prevention and treatment by passive immunization. Acta Biochimica Polonica. 2014;61:573–587. PMID:25210721
   PubMed Web of Science ®Google Scholar
• Brandenburg B, Koudstaal W, Goudsmit J, Klaren V, Tang C, Bujny MV, Korse HJ, Kwaks T, Otterstrom JJ, Juraszek J, et al. Mechanisms of hemagglutinin targeted influenza virus neutralization. PLos One. 2013;8:e80034. doi:10.1371/journal.pone.0080034. PMID:24348996
   PubMed Web of Science ®Google Scholar
• Paules CI, Lakdawala S, McAuliffe JM, Paskel M, Vogel L, Kallewaard NL, Zhu Q, Subbarao K. An HA stem antibody MEDI8852 prevents and controls disease and limits transmission of pandemic influenza viruses. J Inf Dis. 2017;216:356–365. doi:10.1093/infdis/jix292
   PubMed Web of Science ®Google Scholar
• Shaughnessy AF. Monoclonal antibodies: Magic bullets with a hefty price tag. British Medical Journal. 2012;345:e8346[doi:10.1136/bmj.e8346. PMID:23236036
   PubMed Web of Science ®Google Scholar
• Balazs AB, Bloom JD, Hong CM, Rao DS, Baltimore D. Broad protection against influenza infection by vectored immunoprophylaxis in mice. Nature Biotechnol. 2013;3:647–652. doi:10.1038/nbt.2618
   Web of Science ®Google Scholar
• Berry CM, Penhale WJ, Sangster MY. Passive broad-spectrum influenza immunoprophylaxis. Influenza Research and Treatment. 2014;2014:e267594. doi:10.1155/2014/267594
   PubMedGoogle Scholar
• Zheng X, Wong G, Zhao Y, Wang H, He S, Bi Y, Chen W, Jin H, Gai W, Chu D, et al.. Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection. Scientific Reports. 2016;6:24179. doi:10.1038/srep24179. PMID:27067649
   PubMed Web of Science ®Google Scholar
• Seifert SA, Boyer LV. Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies. Ann Emerg Med. 2001;37:189–195. doi:10.1067/mem.2001.113135. PMID:11174238
   PubMed Web of Science ®Google Scholar
• Herbreteau CH, Jacquot F, Rith S, Vacher L, Nguyen L, Carbonnelle C, Lotteau V, Jolivet M, Raoul H, Buchy P, et al. Specific polyclonal F(ab’) neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice. Immunother. 2014;6:699–708. doi:10.2217/imt.14.40
   PubMed Web of Science ®Google Scholar
• Rinaldi C, Penhale WJ, Stumbles PA, Tay G, Berry CM. Modulation of innate immune responses by influenza-specific ovine polyclonal antibodies used for prophylaxis. PLoS ONE. 2014;9:e89674. doi:10.1371/journal.pone.0089674. PMID:24586955
   PubMed Web of Science ®Google Scholar
• Deal CE, Balazs AB. Engineering humoral immunity as prophylaxis or therapy. Curr. Opin. Immunol. 2015;35:113–122. doi:10.1016/j.coi.2015.06.014. PMID:26183209
   PubMed Web of Science ®Google Scholar